Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Array BioPharma Inc.

Advances in™ BRAF/MEK Inhibitors for the Treatment of Advanced Melanoma

Release Date: May 31, 2018
Expiration Date: May 31, 2019
Media: Internet - based


Activity Overview

This activity, Advances in™ BRAF/MEK Inhibitors for the Treatment of Advanced Melanoma, developed in Physicians’ Education Resource, LLC, (PER®) established Advances in™ legacy format, will highlight best practices in the treatment and management of patients with advanced melanoma, including an extensive update on the biologic rationale, current foundation of evidence, and next steps to integrate the use of BRAF/MEK inhibitors for the treatment of advanced melanoma. Additional focus will be placed on BRAF testing, sequencing strategies, and adverse events related to these targeted combination strategies. You will hear expert perspectives and discussions of recent updates that have the potential to advance the treatment of melanoma in the context of current treatment paradigms to improve outcomes for your patients.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Array BioPharma Inc.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, researchers, dermatologists, and surgical oncologists who treat patients with melanoma. Nurse practitioners, nurses, physician assistants, pharmacists, and other healthcare professionals interested in the treatment of melanoma are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  1. Assess recent advances in the understanding of melanoma treatment resistance that provides the mechanistic rationale for BRAF/MEK inhibitor strategies in the context of current management paradigms
  2. Apply knowledge of efficacy profiles on emerging BRAF/MEK combination approaches to inform sequencing decisions that optimize outcomes in patients with melanoma
  3. Apply best practices to proactively identify and manage adverse events associated with combination strategies in the setting of advanced melanoma
  4. Outline key aspects of ongoing clinical trials examining emerging BRAF/MEK combination strategies in melanoma

Faculty, Staff, and Planners' Disclosures


Michael A. Postow, MD
Melanoma and Immunotherapeutics Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant/Research Support: BMS, Infinity, Rgenix, Novartis, Array BioPharma; Consultant: BMS, NewLink Genetics, Merck, Incyte, Novartis, Array BioPharma

Geoffrey T. Gibney, MD
Co-Leader, Melanoma/Skin Cancer Program
Member, Developmental Therapeutics Program
George Lombardi Comprehensive Cancer Center
Chevy Chase, MD

Disclosure: Consultant: Genentech, Novartis, Incyte, NewLink Genetics; Speakers Bureau: Merck, Genentech

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®  or any of the companies that provided commercial support for this activity..

Become a Member

Forgot Password?
Calendar of Events
Filter By